DOCSLIB.ORG

CDISC SEND Controlled Terminology, 2014-03-28

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CDISC SEND Controlled Terminology, 2014-03-28 CDISC SEND Controlled Terminology, 2014-03-28 Source: NCI EVS Terminology Resources website: http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/cdisc NCI CDISC Submission Codelist Name CDISC Definition Codelist Code Value Extensible C66781 AGEU Age Unit Those units of time that are routinely used to express the age of a subject. No C89959 BGTEST Body Weight Gain Terminology for the test names concerned with the increase in overall body Yes Test Name mass. C89960 BGTESTCD Body Weight Gain Terminology for the test codes concerned with the increase in overall body Yes Test Code mass. C88026 BODSYS Body System The terminology that includes concepts relevant to anatomical structure Yes that consists of organs and organ subclasses responsible for certain body functions. C89961 BWTEST Body Weight Test Terminology for the test names concerned with the measurement of body Yes Name mass. C89962 BWTESTCD Body Weight Test Terminology for the test codes concerned with the measurement of body Yes Code mass. C89963 CLCAT Category for Clinical Terminology related to classifications that describe and group clinical Yes Observation observations. C66786 COUNTRY Country A collective generic term that refers here to a wide variety of No dependencies, areas of special sovereignty, uninhabited islands, and other entities in addition to the traditional countries or independent states. (NCI) C90018 CSTATE Consciousness State Terminology related to the sense of awareness of self and of the Yes environment. C89965 DDTEST Death Diagnosis Test Terminology for the test names concerned with the circumstance or No Name condition that results in the death of a living being. C89966 DDTESTCD Death Diagnosis Test Terminology for the test codes concerned with the circumstance or No Code condition that results in the death of a living being. C89967 DESIGN Study Design Terminology related to the plan detailing how a study will be performed in Yes order to represent the phenomenon under examination, to answer the research questions that have been asked, and defining the methods of data analysis. C99074 DIR Directionality CDISC terminology for anatomical location or specimen further detailing Yes directionality. C89968 DSDECOD Standardized Terminology related to the final disposition of the subject in a study. No Disposition Term C90012 EGCATSND SEND ECG Category Terminology related to classifications that describe SEND ECG tests. Yes C90013 EGLEAD ECG Lead Terminology related to electrocardiogram lead names. Yes C71151 EGMETHOD ECG Test Method Terminology codelist used with ECG Test Methods within CDISC. Yes C71150 EGSTRESC ECG Result Terminology codelist used with ECG Findings and Abnormalities within Yes CDISC. C71152 EGTEST ECG Test Name Terminology codelist used with ECG Test Names within CDISC. Yes C71153 EGTESTCD ECG Test Code Terminology codelist used with ECG Tests within CDISC. Yes C71113 FREQ Frequency The terminology that includes terms pertaining to frequency within CDISC. Yes C66726 FRM Pharmaceutical The form of the completed pharmaceutical product, e.g. tablet, capsule, Yes Dosage Form injection, elixir, suppository. Dosage form can have a significant effect on the onset, duration and intensity of the pharmacological action of a drug. A pharmaceutical dosage form controls the rate at which the drug is released into the biological fluids. This release rate affects its intrinsic absorption pattern and therefore, the bioavailability of the drug. C89969 FWTEST Food and Water Terminology for the test names concerned with the subject's consumption Yes Consumption Test of food and/or water. Name C89970 FWTESTCD Food and Water Terminology for the test codes concerned with the subject's consumption of Yes Consumption Test food and/or water. Code C99073 LAT Laterality CDISC terminology for anatomical location or specimen further detailing Yes the side(s) of interest. C67154 LBTEST Laboratory Test Name Terminology used for laboratory test names of the CDISC Standard Data Yes Tabulation Model. page 1 of 395 NCI CDISC Submission Codelist Name CDISC Definition Codelist Code Value Extensible C65047 LBTESTCD Laboratory Test Code Terminology used for laboratory test codes of the CDISC Standard Data Yes Tabulation Model. C89971 MATEST Macroscopic Findings Terminology for the test names concerned with the findings from a Yes Test Name specimen that are visible to the naked eye. C89972 MATESTCD Macroscopic Findings Terminology for the test codes concerned with the findings from a Yes Test Code specimen that are visible to the naked eye. C90017 MIRESCAT Microscopic Terminology related to the classifications of the results from a microscopic Yes Histopathology Result histopathological analysis. Category C89973 MITEST Microscopic Findings Terminology for the test names concerned with the findings from a Yes Test Name specimen that are visible by microscopic analysis. C89974 MITESTCD Microscopic Findings Terminology for the test codes concerned with the findings from a Yes Test Code specimen that are visible by microscopic analysis. C89975 MTHTRM Method of Terminology related to the method by which an experimental organism is Yes Termination euthanized. This includes events that occur as a step in the induction of death. C66789 ND Not Done Indicates a task, process or examination that has either not been initiated No or completed. (NCI) C88025 NEOPLASM Neoplasm Type The terminology that includes concepts relevant to benign or malignant Yes tissue growth. C90004 NEOSTAT Neoplastic Status Terminology related to the classifications of the results from a No histopathological analysis of a tumor. C66742 NY No Yes Response A term that is used to indicate a question with permissible values of No yes/no/unknown/not applicable. C89976 OMTEST Organ Measurement Terminology for the test names concerned with the measurement of No Test Name organs. C89977 OMTESTCD Organ Measurement Terminology for the test codes concerned with the measurement of organs. No Test Code C95120 PHSPRP Physical Properties Terminology relevant to the test names that describe the physical Yes Test Name characteristics of an entity. C95121 PHSPRPCD Physical Properties Terminology relevant to the test codes that describe the physical Yes Test Code characteristics of an entity. C85493 PKPARM PK Parameters Parameters used to describe the time-concentration curve. Yes C85839 PKPARMCD PK Parameters Code Parameter codes used to describe the time-concentration curve. Yes C85494 PKUNIT PK Parameter Units of Units of measure needed for pharmacokinetic parameters. Yes Measure C99075 PORTOT Portion/Totality Qualifier for anatomical location or specimen further detailing the portion or Yes totality, which means arrangement of, or apportioning of an entity. C71148 POSITION Position Terminology codelist used with Body Position within CDISC. Yes C78737 RELTYPE Relationship Type The description of relationship types between a record or set of records. No C66729 ROUTE Route of The course by which a substance was administered in order to reach the Yes Administration site of action in the body. C89981 SBCCDSND SEND Subject Terminology for the test codes concerned with the distinguishing qualities Yes Characteristics Test or prominent aspect of a person, object, action, process, or substance. Code C89980 SBCSND SEND Subject Terminology for the test names concerned with the distinguishing qualities Yes Characteristics Test or prominent aspect of a person, object, action, process, or substance. Name C111113 SDOMAIN SEND Domain A unique, 2-character domain code used in the regulatory submission Yes Abbreviation process of pre-clinical studies. The domain abbreviation is used consistently throughout the submission, i.e. in the dataset name, as the value of the domain variable within the dataset, and as a prefix for most variable names in the dataset. C90000 SEV Severity SEND terminology related to the degree of an occurrence of something No undesirable. C66731 SEX Sex The assemblage of physical properties or qualities by which male is No distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female. (NCI) page 2 of 395 NCI CDISC Submission Codelist Name CDISC Definition Codelist Code Value Extensible C66732 SEXPOP Sex of Participants The specific sex, either male, female, or mixed of the subject group being No studied. (NCI) C89982 SNDIGVER SEND Implementation Terminology related to the version of the SEND implementation guide that Yes Guide Version is in use for the study. C77529 SPEC Specimen Terminology related to any material sample taken from a biological entity. Yes C77808 SPECIES Species Terminology related to the common name for an animal used as the test Yes system in a study (e.g., dog, monkey, mouse, rabbit, rat). C90003 SSTYP SEND Study Type The further classification of nonclinical studies performed e.g. absorption, Yes distribution and metabolism. C90002 STCAT Study Category The type of nonclinical study performed e.g. pharmacokinetics, safety Yes pharmacology and toxicology. C77530 STRAIN Strain/Substrain Terminology used to identify the vendor-supplied species, strain, substrain Yes or breed designation for the test system under study. It may combine the species, background strain, substrain, and associated genetic modifications as supplied by the vendor (e.g., C57BL/6, A/J, B6.129-Pparg<tm2Rev>/J, FISCHER 344, SPRAGUE-DAWLEY IGS, WISTAR Kyoto, BEAGLE, CYNOMOLGUS, RHESUS and CHIMPANZEE). C90007 STSPRM SEND Trial Summary Terminology
Load more

Recommended publications
  • California Tumor Tissue Registry Eighty-Eighth Semi
    CALIFORN IA TUMOR TISSUE REGISTRY EIGHTY-EIGHTH SEMI -ANNUAL SLIDE SEMINAR ON TUMORS OF THE CENTRAL NERVOUS SYSTEM MODERATOR: BERN W. SCHti THAUER, M. D. HEAD SECTION OF SURGICAL PATHOLOGY MAYO CLINIC PROFESSOR OF PATHOLOGY ROCHESTER, MINNESOTA CHAIRMAN: PHILIP VAN HALE, M. D. ASSOCIATE PATHOLOGIST HUNTINGTON MEMORIAL HOSP ITAL PASADENA, CALIFORNIA SUNDAY - JUNE 3, 1990 9:00 A.M. - 5:00 P.M. REGISTRATION: 7:30 A.M. SHERATON PLAZA LA REINA ~OTEL LOS ANGELES, CALIFORNIA (213) 642-1111 Please bring your protocol, but do not bring slides or microscopes to the meeting. CONTRIBUTOR: Bernd W. Scheithauer, M. 0. JUNE 1990 - CASE NO. 1 Rochester, Minnesota TISSUE FROM: Brain, left temporal parietal lobe ACCESSION NO. 26731 CLINICAL ABSTRACT : The patient is a 46 -year-old white ma le wh o experienced a head injury in 1960 but had no history of neurologic disturbances until 1982 at which time he noted the sudden onset of expressive aphasia. CT scan demonstrated a hypodense left temporoparietal lesion associated with a cyst. No enhancement was seen. - The patient elected to be medically observed over a five year interval, there being no intervention until symptoms interfered with his lifestyle. During that time he was maintained on phenobabital. The frequen cy of his partial complex seizures, which were characterized by expressive more than receptive aphasia, varied from one per month to six per week. They lasted from 1 to 30 minutes. No sensorimotor component was ever observed. Memory deficits followed the episodes. The first evidence of tumor enhancement was noted in 1984 and was seen to be somewhat more extensive in a 1986 study.
    [Show full text]
  • Enteric Peripheral Neuroblastoma in a Calf
    NOTE Pathology Enteric peripheral neuroblastoma in a calf Yusuke SAKAI1)*, Masato HIYAMA2), Saya KAGIMOTO1), Yuki MITSUI1, Miko IMAIUMI1), Takeshi OKAYAMA3), Kaori HARADONO3), Masashi SAKURAI1) and Masahiro MORIMOTO1) 1)Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi-shi, Yamaguchi 753-8515, Japan 2)Laboratory of Large Animal Clinical Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi-shi, Yamaguchi 753-8515, Japan 3)Tobu Large Animal Clinic, NOSAI Yamaguchi, 512-2 Kuhara, Shuto-cho, Iwakuni-shi, Yamaguchi 742-0417, Japan ABSTRACT. An 11-month-old female Japanese Black calf had showed chronic intestinal J. Vet. Med. Sci. symptoms. A large mass surrounding the colon wall that was continuous with the colon 81(6): 824–827, 2019 submucosa was surgically removed. After recurrence and euthanasia, a large mass in the colon region and metastatic masses in the omentum, liver, and lung were revealed at necropsy. doi: 10.1292/jvms.18-0450 Pleomorphic small cells proliferated in the mass and muscular layer of the colon. The cells were positively stained with anti-doublecortin (DCX), PGP9.5, nestin, and neuron specific enolase (NSE). Thus, the diagnosis of peripheral neuroblastoma was made. This is the first report of enteric Received: 31 July 2018 peripheral neuroblastoma in animals. Also, clear DCX staining signal suggested usefulness of DCX Accepted: 31 March 2019 immunohistochemistry to differentiate the neuroblastoma from other small cell tumors in cattle. Published online in J-STAGE: cattle, doublecortin, neuronal marker, neuronal neoplasm, peripheral neuroblastoma 9 April 2019 KEY WORDS: Neuroblastoma is an embryonal neuroectodermal neoplasm with limited neuronal differentiation that arises both in the central and peripheral nervous systems [12].
    [Show full text]
  • A Molecular Target for Human Glioblastoma
    Kuan et al. BMC Cancer 2010, 10:468 http://www.biomedcentral.com/1471-2407/10/468 RESEARCH ARTICLE Open Access MRP3: a molecular target for human glioblastoma multiforme immunotherapy Chien-Tsun Kuan1,2*†, Kenji Wakiya1,2†, James E Herndon II2, Eric S Lipp2, Charles N Pegram1,2, Gregory J Riggins3, Ahmed Rasheed1, Scott E Szafranski1, Roger E McLendon1,2, Carol J Wikstrand4, Darell D Bigner1,2* Abstract Background: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3). Methods: We investigated MRP3 by genetic and immunohistochemical (IHC) analysis of human gliomas to determine the incidence, distribution, and localization of MRP3 antigens in GBM and their potential correlation with survival. To determine MRP3 mRNA transcript and protein expression levels, we performed quantitative RT-PCR, raising MRP3-specific antibodies, and IHC analysis with biopsies of newly diagnosed GBM patients. We used univariate and multivariate analyses to assess the correlation of RNA expression and IHC of MRP3 with patient survival, with and without adjustment for age, extent of resection, and KPS. Results: Real-time PCR results from 67 GBM biopsies indicated that 59/67 (88%) samples highly expressed MRP3 mRNA transcripts, in contrast with minimal expression in normal brain samples. Rabbit polyvalent and murine monoclonal antibodies generated against an extracellular span of MRP3 protein demonstrated reactivity with defined MRP3-expressing cell lines and GBM patient biopsies by Western blotting and FACS analyses, the latter establishing cell surface MRP3 protein expression.
    [Show full text]
  • Abnormality of the Middle Phalanx of the 4Th Toe Abnormality of The
    Glucocortocoid-insensitive primary hyperaldosteronism Absence of alpha granules Dexamethasone-suppresible primary hyperaldosteronism Abnormal number of alpha granules Primary hyperaldosteronism Nasogastric tube feeding in infancy Abnormal alpha granule content Poor suck Nasal regurgitation Gastrostomy tube feeding in infancy Abnormal alpha granule distribution Lumbar interpedicular narrowing Secondary hyperaldosteronism Abnormal number of dense granules Abnormal denseAbnormal granule content alpha granules Feeding difficulties in infancy Primary hypercorticolismSecondary hypercorticolism Hypoplastic L5 vertebral pedicle Caudal interpedicular narrowing Hyperaldosteronism Projectile vomiting Abnormal dense granules Episodic vomiting Lower thoracicThoracolumbar interpediculate interpediculate narrowness narrowness Hypercortisolism Chronic diarrhea Intermittent diarrhea Delayed self-feeding during toddler Hypoplastic vertebral pedicle years Intractable diarrhea Corticotropin-releasing hormone Protracted diarrhea Enlarged vertebral pedicles Vomiting Secretory diarrhea (CRH) deficient Adrenocorticotropinadrenal insufficiency (ACTH) Semantic dementia receptor (ACTHR) defect Hypoaldosteronism Narrow vertebral interpedicular Adrenocorticotropin (ACTH) distance Hypocortisolemia deficient adrenal insufficiency Crohn's disease Abnormal platelet granules Ulcerative colitis Patchy atrophy of the retinal pigment epithelium Corticotropin-releasing hormone Chronic tubulointerstitial nephritis Single isolated congenital Nausea Diarrhea Hyperactive bowel
    [Show full text]
  • Sinonasal Tumors
    Prepared by Kurt Schaberg Sinonasal/Nasopharyngeal Tumors Benign Sinonasal Papillomas aka Schneiderian papilloma Morphology Location Risk of Molecular transformation Exophytic Exophytic growth; Nasal Very low risk Low-risk HPV immature squamous epithelium septum subtypes Inverted Inverted ‘‘ribbonlike’’ growth; Lateral Low to EGFR immature squamous epithelium; wall and Intermediate risk mutations or transmigrating intraepithelial sinuses low-risk HPV neutrophilic inflammation subtypes Oncocytic Exophytic and endophytic growth; Lateral Low to KRAS multilayered oncocytic epithelium; wall and intermediate microcysts and intraepithelial sinuses neutrophilic microabscesses Modified from: Weindorf et al. Arch Pathol Lab Med—Vol 143, November 2019 Oncocytic Sinonasal Papilloma Note the abundant oncocytic epithelium with numerous neutrophils Inverted Sinonasal Papilloma Note the inverted, “ribbon-like” growth Respiratory Epithelial Adenomatoid Hamartoma aka “REAH” Sinonasal glandular proliferation arising from the surface epithelium (i.e., in continuity with the surface). Invaginations of small to medium-sized glands surrounded by hyalinized stroma with characteristic thickened, eosinophilic basement membrane Exists on a spectrum with seromucinous hamartoma, which has smaller glands. Should be able to draw a circle around all of the glands though, if too confluent → consider a low-grade adenocarcinoma Inflammatory Polyp Surface ciliated, sinonasal mucosa, possibly with squamous metaplasia. Edematous stroma (without a proliferation of seromucinous glands). Mixed inflammation (usu. Lymphocytes, plasma cells, and eosinophils) Pituitary adenoma Benign anterior pituitary tumor Although usually primary to sphenoid bone, can erode into nasopharynx or be ectopic Can result in endocrine disorders, such as Cushing’s disease or acromegaly. Solid, nested, or trabecular growth of epithelioid cells with round nuclei and speckled chromatin and eosinophilic, granular chromatin. Express CK, and neuroendocrine markers.
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]
  • Cerebellar Liponeurocytoma Sreedhar Babu Et Al Case Report: Cerebellar Liponeurocytoma: a Case-Report
    Cerebellar liponeurocytoma Sreedhar Babu et al Case Report: Cerebellar liponeurocytoma: a case-report K.V. Sreedhar Babu,1 A.K. Chowhan,2 N. Rukmangadha,2 B.C.M. Prasad,3 M. Kumaraswamy Reddy2 Departments of 1Immuno Haematology & Blood Transfusion, 2Pathology and 3Neurosurgery, Sri Venkateswara Institute of Medical Sciences, Tirupati ABSTRACT Cerebellar liponeurocytoma is a rare cerebellar neoplasm of adults with advanced neuronal / neurocytic and focal lipomatous differentiation, a low proliferative potential and a favorable clinical prognosis corresponding to World Health Organization grade I or II. Only a few cases have been described in the literature (approximately 20 cases) by different names. A 48-years old female, presented with history of headache and dizziness associated with neck pain; restricted neck movements, drop attacks and occasional regurgitation of food since one year. Magnetic resonance imaging disclosed a right cerebellar mass lesion. Gross total resec- tion of the tumour was accomplished through a suboccipital craniotomy. The excised tissue was diagnosed as cerebellar liponeurocytoma, a rare entity, based on histopathological examination and immunohistochemistry. The morphological appearance of this neoplasm can be confused with that of oligodendroglioma, neurocytoma, ependymoma, medulloblastoma, solid hemangioblastoma and metastatic carcinomas etc., with unpredictable prognosis, which require postoperative radiotherapy, hence the importance of accurately diagnosing this rare neoplasm. This tumour should be added to the differential diagnosis of mass lesions of the posterior fossa. Key words: Liponeurocytoma, Cerebellum, Posterior cranial fossa Sreedhar Babu KV, Chowhan AK, Rukmangadha N, Prasad BCM, Kumaraswamy Reddy M. Cerebellar liponeurocytoma: a case- report. J Clin Sci Res 2012;1:39-42. INTRODUCTION liponeurocytoma with clinical, histological, and radiological studies.
    [Show full text]
  • Leptomeningeal Dissemination of a Pediatric Neoplasm with 1P19q Deletion Showing Mixed Immunohistochemical Features of an Oligodendroglioma and Neurocytoma
    Acta Neurochir DOI 10.1007/s00701-010-0674-x CASE REPORT Leptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma Richard B. Rhiew & Sunil Manjila & Andrew Lozen & Murali Guthikonda & Sandeep Sood & William J. Kupsky Received: 24 February 2010 /Accepted: 21 April 2010 # Springer-Verlag 2010 Abstract Leptomeningeal dissemination of an oligoden- Keywords Leptomeningeal dissemination . droglioma is rarely reported in the neurosurgical literature, Oligodenroglioma . Neurocytoma . Mixed tumor especially in cases with a classical 1p19q deletion. The authors describe a case wherein a 1p19q deletion in a disseminated tumor with mixed immunohistochemical Introduction features of oligodendroglioma and neurocytoma was encountered and treated. Stereotactic right frontal craniot- Apart from the diagnostic dilemma of distinguishing omy was undertaken for obtaining definitive histological between neurocytomas and oligodendrogliomas, the recog- diagnosis. The results revealed a neuroectodermal neoplasm nition of rare mixed glial and neurocytic tumors presents an with histologic and immunohistochemical features of obstacle in tumor classification. Reports of leptomeningeal oligodendroglioma and neurocytoma. FISH analysis con- dissemination of tumors in this category are extremely rare, firmed classical 1p19q deletion. The patient was treated particularly those harboring the classic 1p19q co-deletion. postoperatively with chemotherapy and radiation therapy. The authors present such a histological variant of oligoden- He showed good clinical response and remains alive droglioma with evidence of extensive craniospinal lepto- 16 months after diagnosis. meningeal dissemination (LMD). The present case report highlights the importance of recognizing this discrete subtype of low-grade craniospinal neoplasms, which carry : : R. B. Rhiew S. Manjila M. Guthikonda features of both tumors and therefore are not classified Department of Neurosurgery, using the existing WHO system for CNS tumors.
    [Show full text]
  • Ependimoma Sellar: Reporte De Caso Y Revisión De La Literatura
    Ependimoma Sellar: Reporte de Caso y Revisión de la Literatura Fuenmayor-Duche Tatiana [email protected] Residente de Neurocirugía, Hospital de Especialidades Eugenio Espejo, Quito-Ecuador Ortiz-Ordonez Andrea [email protected] Residente de Neurocirugía, Hospital de Especialidades Eugenio Espejo, Quito-Ecuador Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, calle Diego de Robles s/n y Pampite, Quito 170901, Ecuador Bucheli-Quezada Paul [email protected] Residente de Neurocirugía, Hospital de Especialidades Eugenio Espejo, Quito-Ecuador Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, calle Diego de Robles s/n y Pampite, Quito 170901, Ecuador Quintanilla-González Chrystin [email protected] Residente de Neurocirugía, Hospital de Especialidades Eugenio Espejo, Quito-Ecuador Ayala-Ortiz Daniel Alejandro [email protected] Universidad Central del Ecuador RESUMEN El ependimoma es una neoplasia neuroectodérmica cuya localización principal es infratentorial en niños y espinal en adultos. Solo se han informado unos pocos casos de localización sellar atípica y no existe un protocolo de diagnóstico o manejo estandarizado para estos casos. Se informa un caso poco frecuente de ependimoma sellar en un adulto con deterioro cognitivo y visual. La sospecha clínica de esta entidad, así como la máxima resección quirúrgica segura, pueden permitir un diagnóstico certero y mejorar el abordaje terapéutico. Se necesitan más estudios sobre este tema para evaluar el tratamiento y la supervivencia a largo plazo. Palabras clave: Ependimoma intracraneal del adulto, Silla turca, Neurocirugía Ciencia Latina Revista Científica Multidisciplinar, Ciudad de México, México. ISSN 2707-2207 / ISSN 2707-2215 (en línea), mayo-junio, 2021, Volumen 5, Número 3.
    [Show full text]
  • DNA Methylation-Based Reclassification of Olfactory Neuroblastoma
    manuscript Click here to download manuscript Capper Engel Stichel et al. manuscript revision v9.docx Click here to view linked References DNA methylation-based reclassification of olfactory neuroblastoma David Capper1, 2, 13 *, Nils W. Engel3, 4 *, Damian Stichel1 *, Matt Lechner5, 6, 7, Stefanie Glöss13, Simone Schmid13, Christian Kölsche1, 2, Daniel Schrimpf1, 2, Judith Niesen23, 24, Annika K. Wefers1, 2, David T. W. Jones8, 9, Martin Sill8, 9, Oliver Weigert10, Keith L. Ligon11, Adriana Olar12, Arend Koch13, Martin Forster6, 7, Sebastian Moran26, Oscar M. Tirado27, Miguel Sáinz-Japeado27, Jaume Mora28, Manel Esteller26, 29, 30, Javier Alonso31, Xavier Garcia del Muro32, Werner Paulus14, Jörg Felsberg15, Guido Reifenberger15, Markus Glatzel16, Stephan Frank17, Camelia M. Monoranu18, Valerie J. Lund5, 7, Andreas von Deimling1, 2, Stefan Pfister8, 9, 25, Rolf Buslei19 +, Julika Ribbat-Idel20 ⱡ, Sven Perner20, ⱡ, Volker Gudziol21, Matthias Meinhardt22 and Ulrich Schüller3, 16, 23, 24 * These authors contributed equally to this work Correspondence should be addressed to U.S. ([email protected]), tel.: +49 (0) 40 7410 – 54968, fax: +49 (0) 40 7410 - 40350 1 Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany 2 Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany 3 Center for Neuropathology, Ludwig-Maximilians-University, Munich, Germany 4 Department of Oncology and Hematology with Sections Bone Marrow Transplant and Pneumology, Hubertus
    [Show full text]
  • Summary Review I Have Focused on the Most Significant Complication of Bradycardia, I.E., CV Death
    CV = cardiovascular; HF = heart failure; HR = heart rate; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction; MI = myocardial infarction The results of these three outcome trials are complex, inconsistent, and difficult to interpret. On the one hand SHIFT appears to demonstrate a highly significant benefit for HF hospitalizations in HF patients with higher heart rates and intolerant of, or inadequately dosed with, BBs. Mortality in SHIFT leans favorable. On the other hand BEAUTIFUL (Fox, Ford et al. 2008) failed to show any HF hospitalization or mortality benefit in IHD patients with reduced systolic function. While BEAUTIFUL suggested an MI benefit not seen in SHIFT, the large confirmatory trial SIGNIFY (Fox, Ford et al. 2014) failed to confirm this benefit and even suggests a detrimental impact in patients with symptomatic angina. Furthermore, SHIFT was performed entirely outside the U.S. with practice patterns, e.g., little intracardiac defibrillator (ICD) and cardiac resynchronization therapy (CRT) use, differing from U.S. guidelines and raising the issue of relevance to U.S. practice. Additionally, analyses of SHIFT suggest several significant drug interactions and subgroup variations. In this review I present the data addressing all of these issues. Finally, I propose and justify a modified indication for ivabradine use in HF patients. 2. Background/Regulatory History/Previous Actions/Foreign Regulatory Actions/Status All studies were not conducted under U.S. IND. Ivabradine was approved in Europe for the treatment of angina in 2005 and in 2012 for the treatment of heart failure (HF) in patients in sinus rhythm and whose heart rate is ≥ 75 bpm in combination with standard therapy including beta blockers (BBs) or when beta blockers are not tolerated.
    [Show full text]
  • Clinical Content Data Points Dictionary
    Abstracted Primary Childhood Cancer Diagnoses within Abstracted Diagnosis Groups Data Freeze: June 30, 2017 Broad Diagnosis Group (diaggrp) Diagnosis (diag) Acute lymphoblastic leukemia Acute Lymphoblastic Leukemia, B Lineage, Bone Marrow Acute Lymphoblastic Leukemia, B-Cell, Bone Marrow Acute Lymphoblastic Leukemia, B-Cell, Mature, Bone Marrow Acute Lymphoblastic Leukemia, B-Lineage, Transitional, Bone Marrow Acute Lymphoblastic Leukemia, Bone Marrow Acute Lymphoblastic Leukemia, Common , Bone Marrow Acute Lymphoblastic Leukemia, Common Pre B, Bone Marrow Acute Lymphoblastic Leukemia, Common, Early Pre B, Bone Marrow Acute Lymphoblastic Leukemia, Early B, Bone Marrow Acute Lymphoblastic Leukemia, Early Pre B, Bone Marrow Acute Lymphoblastic Leukemia, Early Pre B, Hematological Acute Lymphoblastic Leukemia, Early Pre-B, Atypical, Bone Marrow Acute Lymphoblastic Leukemia, Early T Cell Precursor, Bone Marrow Acute Lymphoblastic Leukemia, Mixed Early Pre B And Pre B, Bone Marrow Acute Lymphoblastic Leukemia, Mixed Pre B And Mature B, Bone Marrow Acute Lymphoblastic Leukemia, Non B, Non Pre B, Bone Marrow Acute Lymphoblastic Leukemia, Pre B And Pre B Transitional, Bone Marrow Acute Lymphoblastic Leukemia, Pre-B, Bone Marrow Acute Lymphoblastic Leukemia, Pre-T Cell, Bone Marrow Acute Lymphoblastic Leukemia, Progenitor B Cell, Bone Marrow Acute Lymphoblastic Leukemia, T-Cell, Bone Marrow Acute Lymphoblastic Leukemia, Transitional Pre B, Bone Marrow Acute Lymphoblastic Leukemia, Undifferentiated, Bone Marrow T Cell Large Granular Lymphocytic
    [Show full text]